Bill Sibold
Bill Sibold is responsible for building Sanofi’s global leadership position in Specialty Care, with a focus on immunology, neurology, oncology, rare diseases and rare blood disorders, and oversees the global launch strategy for key products. In his role as President, Sanofi North America, Bill leads the coordination of Sanofi’s business in North America, across all global business units and functions. Bill has more than 25 years of experience in the biopharmaceutical industry. He began his career with Eli Lilly and then held several leadership positions within Biogen, including driving its US commercial operations in neurology, oncology and rheumatology. He also …
Bill Sibold is responsible for building Sanofi’s global leadership position in Specialty Care, with a focus on immunology, neurology, oncology, rare diseases and rare blood disorders, and oversees the global launch strategy for key products. In his role as President, Sanofi North America, Bill leads the coordination of Sanofi’s business in North America, across all global business units and functions.
Bill has more than 25 years of experience in the biopharmaceutical industry. He began his career with Eli Lilly and then held several leadership positions within Biogen, including driving its US commercial operations in neurology, oncology and rheumatology. He also served as Chief Commercial Officer at Avanir Pharmaceuticals. Bill joined Sanofi in 2011 as Head of the Multiple Sclerosis franchise. In January 2016, he became Head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization. He was appointed to his current position in 2017.
Bill holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.
Bill is a husband and the father of three children. He loves sports and is a big New England Patriots fan (American football).
See more
Bill has more than 25 years of experience in the biopharmaceutical industry. He began his career with Eli Lilly and then held several leadership positions within Biogen, including driving its US commercial operations in neurology, oncology and rheumatology. He also served as Chief Commercial Officer at Avanir Pharmaceuticals. Bill joined Sanofi in 2011 as Head of the Multiple Sclerosis franchise. In January 2016, he became Head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization. He was appointed to his current position in 2017.
Bill holds an MBA from Harvard Business School and a BA in Molecular Biophysics and Biochemistry from Yale University.
Bill is a husband and the father of three children. He loves sports and is a big New England Patriots fan (American football).
Articles: Bill Sibold
Sanofi Genzyme EVP Bill Sibold Reflects on 30 Years of Rare Disease CSR Program
Global / Bill Sibold, Executive Vice President and Head of Sanofi Genzyme, highlights the achievements of the company’s Rare Humanitarian Program over the last 30 years, bringing treatments to patients in developing countries with lysomal storage disorders who would otherwise not have access. Sibold outlines the persistent obstacles facing people with rare diseases and the work that…
Latest Report
